Dr. Lal Path Labs Ltd. has informed the Exchange about Agreements
LALPATHLAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Dr. Lal PathLabs' Board, via circular resolution on September 23, 2025, approved the acquisition of an immovable property in New Delhi for a consolidated consideration of up to ₹74.51 Crores (excluding stamp duty, registration fees, brokerage, and other incidental costs). The property comprises four units (101, 102 on the first floor and 201, 202 on the second floor), a ground-floor shop, basement usage rights, and designated parking, located at Plot No. Site-II, District Centre, Shalimar Palace, Shalimar Bagh, New Delhi. The transaction is between the company, South Indian Bank Limited (lender), the existing mortgagors/borrowers, and Aggarwal Towers Private Limited (builder). The deal is not a related party transaction and is subject to necessary regulatory approvals and consents.
The acquisition is a routine real estate purchase, likely for expanding the company's diagnostic network in the Delhi-NCR region. At ~₹74.5 Crores, the size is modest relative to the company's overall scale and net worth, and is unlikely to materially move the stock. Shareholders may view it as a positive step toward capacity expansion if executed.